Table 1.

Clinical and demographic characteristics of donor/recipient

VariableAll PatientsDonor 50–59 yr (Group A)Donor 60–69 yr (Group B)Donor 70–79 yr (Group C)Donors ≥80 yr (Group D)P Value
Donor characteristics
 Men/women, %45.0/55.053.8/46.240.9/59.145.3/54.751.9/48.10.16
 Estimated creatinine clearance, ml/min85.2±27.9106.9±31.187.1±24.878.7±25.862.5±19.8<0.001
 eGFR CKD-EPI, ml/min per 1.73 m282.6±23.988.1±27.483.9±23.680.4±22.173.8±19.9<0.001
 Hypertension, %72.494.568.667.770.8<0.001
 DM, %10.311.1137.59.10.27
 Cerebrovascular cause of death, %85.210083.580.388.5<0.001
Recipient characteristics
 Men/women, %63.7/36.362.6/37.459.1/40.968.3/31.766.7/33.30.08
 Mean age, yr59.2±9.452.4±8.957.6±9.462.8±8.062.5±7.4<0.001
 First Tx/more than one Tx, %573/74 (88.6/11.4)73/18 (80.2/19.8)232/32 (87.9/12.1)242/23 (91.3/8.7)26/1 (96.3/3.7)0.02
 SKT/DKT, %606/41 (93.7/6.3)90/1 (98.9/1.1)253/11 (95.8/4.2)247/18 (93.2/6.8)16/11 (59.3/40.7)<0.001
 PD/HD, %23.8/76.215.9/84.120.8/79.228.8/71.222.2/77.80.04
 Median dialysis duration before transplantation (25th; 75th percentiles), yr4.0 (2.1; 6.7)4.9 (2.0; 9.7)3.5 (2.0; 6.5)4.3 (2.3; 6.5)4.4 (1.5; 7.6)0.51
 Pretransplant DM type 1 or 2, %13.911.212.616.612.80.55
 Pretransplant HCV POS, %9.19.59.87.5120.85
Transplant baseline characteristics
 HLA A/B/DR MM (0–2/3–4/5–6), %28/71.3/0.733/67/034.9/64/1.120.8/78.5/0.714.8/85.2/00.15
 Negative PRA (CDC) at transplantation, %88.184.686.090.992.60.19
 Cold ischemia time, h18.3±4.717.5±4.418.3±4.918.2±4.719.0±3.80.42
  • CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DM, diabetes mellitus; Tx, transplant; SKT, single-kidney transplantation; DKT, dual-kidney transplantation; PD, peritoneal dialysis; HD, hemodialysis; HCV POS, positive for hepatitis C virus; MM, mismatch; PRA, panel reactive antibody; CDC, cell-dependent cytotoxicity.